JP2023504187A5 - - Google Patents
Info
- Publication number
- JP2023504187A5 JP2023504187A5 JP2022533071A JP2022533071A JP2023504187A5 JP 2023504187 A5 JP2023504187 A5 JP 2023504187A5 JP 2022533071 A JP2022533071 A JP 2022533071A JP 2022533071 A JP2022533071 A JP 2022533071A JP 2023504187 A5 JP2023504187 A5 JP 2023504187A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024151893A JP2024170517A (ja) | 2019-12-05 | 2024-09-04 | 抗αｖβ６抗体及び抗体薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943959P | 2019-12-05 | 2019-12-05 | |
| US62/943,959 | 2019-12-05 | ||
| US202063012584P | 2020-04-20 | 2020-04-20 | |
| US63/012,584 | 2020-04-20 | ||
| PCT/US2020/063390 WO2021113697A1 (en) | 2019-12-05 | 2020-12-04 | Anti-avb6 antibodies and antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024151893A Division JP2024170517A (ja) | 2019-12-05 | 2024-09-04 | 抗αｖβ６抗体及び抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504187A JP2023504187A (ja) | 2023-02-01 |
| JP2023504187A5 true JP2023504187A5 (enExample) | 2024-06-07 |
| JP7551750B2 JP7551750B2 (ja) | 2024-09-17 |
Family
ID=76222033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533071A Active JP7551750B2 (ja) | 2019-12-05 | 2020-12-04 | 抗αｖβ６抗体及び抗体薬物コンジュゲート |
| JP2024151893A Withdrawn JP2024170517A (ja) | 2019-12-05 | 2024-09-04 | 抗αｖβ６抗体及び抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024151893A Withdrawn JP2024170517A (ja) | 2019-12-05 | 2024-09-04 | 抗αｖβ６抗体及び抗体薬物コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11827709B2 (enExample) |
| EP (1) | EP4069297A4 (enExample) |
| JP (2) | JP7551750B2 (enExample) |
| KR (1) | KR20220110231A (enExample) |
| AU (1) | AU2020397070A1 (enExample) |
| BR (1) | BR112022009570A2 (enExample) |
| CA (1) | CA3159414A1 (enExample) |
| IL (1) | IL293195A (enExample) |
| MX (1) | MX2022006132A (enExample) |
| TW (1) | TWI884192B (enExample) |
| WO (1) | WO2021113697A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| KR20250089558A (ko) | 2022-11-03 | 2025-06-18 | 씨젠 인크. | 항-αvβ6 항체 및 항체-약물 접합체 및 암 치료에서의 이의 용도 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4731670A2 (en) | 2023-06-23 | 2026-04-29 | Mythic Therapeutics, Inc. | Ph sensitive anti-itgb6 antibodies and uses thereof |
| AU2024346987A1 (en) * | 2023-09-19 | 2026-04-02 | Telix Targeting Technologies, Inc. | Antigen binding constructs |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| ATE511850T1 (de) | 1997-08-08 | 2011-06-15 | Univ California | Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin |
| EP2165714B1 (en) | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| CA2481922A1 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| AU2005294131A1 (en) | 2004-10-05 | 2006-04-20 | Wyeth | Methods and compositions for improving recombinant protein production |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| WO2006125140A2 (en) | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| AU2006286498A1 (en) | 2005-08-31 | 2007-03-08 | Novo Nordisk Health Care Ag | Human FVII monoclonal antibodies binding the GLA domain and use thereof |
| CN101563105B (zh) | 2006-07-10 | 2013-01-23 | 拜奥根Idec马萨诸塞公司 | 用于抑制smad4-缺陷癌症的组合物和方法 |
| EP2064244B1 (en) | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| JP2010506944A (ja) | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防 |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| EP2241578B1 (en) | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
| JP5467997B2 (ja) | 2008-03-27 | 2014-04-09 | テルモ株式会社 | 生体吸収性材料およびそれを用いた生体内留置物 |
| CA2723842A1 (en) | 2008-05-09 | 2009-11-12 | Peter Vanlandschoot | Amino acid sequences directed against integrins and uses thereof |
| CN102597001B (zh) | 2009-08-19 | 2014-07-30 | 默克专利有限公司 | 在ffpe材料中用于检测整联蛋白复合体的抗体 |
| WO2011046309A2 (en) | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
| SG191716A1 (en) * | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| SG11201404354UA (en) * | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
| HK1208470A1 (en) | 2012-03-29 | 2016-03-04 | Biogen Ma Inc. | Biomarkers for use in integrin therapy applications |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| HK1221725A1 (zh) * | 2013-08-13 | 2017-06-09 | Sanofi | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| CA2925057A1 (en) | 2013-10-01 | 2015-04-09 | Simon T. BARRY | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| US10858427B2 (en) * | 2017-03-10 | 2020-12-08 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Monoclonal antibody against both IL-17A and IL-17F and use of the same |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
| AU2018322475A1 (en) | 2017-08-22 | 2020-03-05 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| GB201814562D0 (en) * | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
-
2020
- 2020-12-04 US US17/112,533 patent/US11827709B2/en active Active
- 2020-12-04 CA CA3159414A patent/CA3159414A1/en active Pending
- 2020-12-04 TW TW109142793A patent/TWI884192B/zh active
- 2020-12-04 KR KR1020227021011A patent/KR20220110231A/ko active Pending
- 2020-12-04 MX MX2022006132A patent/MX2022006132A/es unknown
- 2020-12-04 JP JP2022533071A patent/JP7551750B2/ja active Active
- 2020-12-04 BR BR112022009570A patent/BR112022009570A2/pt unknown
- 2020-12-04 AU AU2020397070A patent/AU2020397070A1/en active Pending
- 2020-12-04 WO PCT/US2020/063390 patent/WO2021113697A1/en not_active Ceased
- 2020-12-04 IL IL293195A patent/IL293195A/en unknown
- 2020-12-04 EP EP20897470.9A patent/EP4069297A4/en active Pending
-
2023
- 2023-10-18 US US18/489,216 patent/US12268751B2/en active Active
-
2024
- 2024-09-04 JP JP2024151893A patent/JP2024170517A/ja not_active Withdrawn
-
2025
- 2025-03-03 US US19/068,074 patent/US20250242041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504187A5 (enExample) | ||
| US11897961B2 (en) | Anti-CD123 antibodies and conjugates and derivatives thereof | |
| US11819553B2 (en) | Glypican 3 antibodies and conjugates thereof | |
| US20240226318A1 (en) | Antibody drug conjugate targeting nectin 4 and preparation method therefor and use thereof | |
| US9822183B2 (en) | CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
| CN106729743B (zh) | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 | |
| JP2021513844A5 (enExample) | ||
| WO2023036137A1 (en) | Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies | |
| JP2015523380A5 (enExample) | ||
| US20050123549A1 (en) | CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
| JP2015523961A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2017534253A5 (enExample) | ||
| JP7510518B2 (ja) | 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用 | |
| JP2012522513A5 (enExample) | ||
| EP4144376A1 (en) | Antibody drug conjugate loaded with double toxins and application thereof | |
| JP2014509835A5 (enExample) | ||
| JP2022530524A5 (enExample) | ||
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2016523810A5 (enExample) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2015533781A5 (enExample) | ||
| AU2005335743A1 (en) | A CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
| JP2015529656A5 (enExample) | ||
| WO2023001300A1 (zh) | 艾日布林衍生物的药物偶联物 |